Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias

作者：Ioannis Karfis, Gwennaëlle Marin, Hugo Levillain, Stylianos Drisis, Raoul Muteganya, Gabriela Critchi, Loubna Taraji-Schiltz, Carlos Artigas Guix, Leila Shaza, Meriem Elbachiri, Laura Mans, Godelieve Machiels, Alain Hendlisz, Patrick Flamen · 发表于：Oncotarget · 年份：2020 · DOI：10.18632/oncotarget.27460 · 被引用次数：38 · 研究领域：Neuroendocrine Tumor Research Advances、Pancreatic and Hepatic Oncology Research、Lung Cancer Research Studies

// Ioannis Karfis 1 , Gwennaëlle Marin 1 , Hugo Levillain 1 , Stylianos Drisis 2 , Raoul Muteganya 1 , Gabriela Critchi 1 , Loubna Taraji-Schiltz 1 , Carlos Artigas Guix 1 , Leila Shaza 3 , Meriem Elbachiri 3 , Laura Mans 3 , Godelieve Machiels 3 , Alain Hendlisz 3 and Patrick Flamen 1 1 Nuclear Medicine Department, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium 2 Radiology/Medical Imaging Department, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium 3 Digestive Oncology Department, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium Correspondence to: Ioannis Karfis, email: ioannis.karfis@bordet.be Keywords: gastroenteropancreatic neuroendocrine neoplasias; molecular imaging; prognostic biomarkers; 68 Ga-DOTATATE PET/CT; 18 F-FDG PET/CT Received: October 02, 2019 Accepted: January 13, 2020 Published: February 11, 2020 ABSTRACT We investigated on the added prognostic value of a three-scale combined molecular imaging with 68 Ga-DOTATATE and 18 F-FDG PET/CT, (compared to Ki-67 based histological grading), in gastroenteropancreatic neuroendocrine neoplasia patients. 85 patients with histologically proven metastatic gastroenteropancreatic neuroendocrine neoplasias, who underwent combined PET/CT imaging were retrospectively evaluated. Highest Ki-67 value available at time of 18 F-FDG PET/CT was recorded. Patients were classified according to World Health Organization/European Neuroendocrine Tumor Soc...